Medications
Retatrutide in New Zealand: what it is, what the trials show, and why you cannot buy it yet
Retatrutide's trials show up to 28 percent average weight loss, yet it is approved nowhere.
Well Revolution
September 20, 2026
The trial results are real, the approval does not exist yet, and the vials sold online are neither
Every few years a medicine earns a nickname before it earns a licence. Right now that medicine is retatrutide, "reta" in the fitness forums and social media feeds, spoken about as the next leap in weight-loss treatment. For once, the hype has real science underneath it. It also has a problem the hype skips over: retatrutide is not approved anywhere in the world, and the only version a New Zealander can currently buy is a vial of powder from the black market that nobody can verify.
Both halves of that are worth understanding properly, because the honest story is genuinely exciting. It is just not a story about something you can have today.
What retatrutide is
Retatrutide is an experimental weekly injection developed by Eli Lilly, the company behind tirzepatide (Mounjaro). The medicines available now work on one appetite-regulating gut hormone system (Wegovy, on GLP-1) or two (Mounjaro, on GLP-1 and GIP). Retatrutide works on three: GLP-1, GIP and the glucagon receptor, which is involved in energy use. The theory is simple enough: more of the body's weight-regulation systems working with you at once.
What the trials actually show
The results have been striking at every stage. In the phase 2 trial published in the New England Journal of Medicine in 2023, participants on the highest dose lost around 24 percent of their body weight on average over 48 weeks, and the weight was still trending down when the trial ended.
The phase 3 programme, called TRIUMPH, began reporting through 2026, and the headline trial, TRIUMPH-1, showed the largest average weight reduction recorded in a phase 3 obesity trial: around 28 percent of body weight over 80 weeks on the highest dose, with a substantial share of participants losing 30 percent or more. Companion trials in people with related conditions reported average losses around 22 percent. Side effects have been broadly familiar from this family of medicines, mostly gut-related, and the full safety picture is exactly what the remaining trial programme and regulators now work through.
Two things belong next to those numbers. First, they came from supervised trials: pharmaceutical-grade medicine at verified doses, stepped up carefully, with medical monitoring and support throughout. The numbers describe that whole package, not a substance in isolation. Second, impressive averages are not a personal guarantee; responses vary person to person, which is one more reason this class of medicine belongs inside real medical care.
Where approval actually stands
Nowhere yet, and that is not a New Zealand quirk. Eli Lilly has indicated it plans to file for its first regulatory approval in the United States in early 2027. After filing comes the review itself, and other regulators, including Medsafe, follow with their own processes after that. Approval timelines are never promises, so the honest summary for New Zealand is: not this year, and no one can responsibly tell you which year.
Until Medsafe approves it, no doctor in New Zealand can prescribe retatrutide and no pharmacy can dispense it. There is no legal source here, full stop.
So what is the "retatrutide" being sold online?
An unknown. This is the black market's oldest trick with new packaging: take a name with genuine trial results attached, print it on a vial, and let the science do the selling. When Re: News investigated New Zealand's peptide trade in 2026, a $200 vial of powder sold as retatrutide was handed over on an Auckland street 42 minutes after first contact. When the NZ Drug Foundation tested black-market peptides, the results were inconclusive: the tests could not confirm which peptide a sample contained, or rule out contaminants.
Remember, every legitimate gram of retatrutide on earth is inside Lilly's manufacturing and trial system. It is not reaching social media sellers in Auckland. Whatever those vials contain, at whatever strength, with whatever else in them, they are not the medicine the trials tested, and injecting them means running an uncontrolled experiment on yourself with none of the safeguards the actual trial participants had. Since December 2025 most of these peptides are prescription medicines in New Zealand, so the trade is unlawful as well as unverifiable. The wider story is in What are "research peptides"?
The good news you do not have to wait for
Here is the part the forums undersell. The gap between "nothing" and "retatrutide someday" is not empty. It holds two Medsafe-approved medicines whose results would have sounded like science fiction a decade ago: Wegovy (semaglutide), averaging around 15 percent body-weight loss in its pivotal trial, and Mounjaro (tirzepatide), averaging around 21 percent. Prescribed today, dispensed by NZ pharmacies today, wrapped in real care today.
And the difference between a good result and a great one usually is not which molecule you are on. It is the treatment around it: protein, strength work, regular eating, sleep, side effects managed early, and a maintenance plan when you get there. Someone doing that work on an approved medicine now will very likely be in better health in two years than someone who spent those years buying mystery vials while waiting for the future to arrive.
If retatrutide does earn its approval, it will arrive here through the same system as every real medicine, and services like ours will be able to offer it properly, with the assessment and support that made its trial results possible in the first place. Watch this space with us. In the meantime, the complete picture of what is available now, how legal access works and how to avoid the traps is in our guide: Weight-loss injections in New Zealand.
This article is general information, not personal medical advice. Your own treatment decisions always come from your prescriber.
Existing members: log in at member.wellrevolution.com and start a priority chat any time you need us.
New to Well Revolution? Start an online weight management assessment and one of our NZ-registered doctors will review whether treatment is right for you.
References
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023;389:514-526. Link
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. 2026. Link
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. 2026. Link
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002. Link
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216. Link
- Madden-Smith Z. $200 got me a vial of peptides in minutes, AI teaches how to inject it. Re: News, via 1News. 17 May 2026. Link
Seeing a doctor is as easy as sending a text
Concerned, need advice, a prescription, refill or referral?
Chat with a GP now
Subscribe to our newsletter
